1st Jun 2015 09:04
LONDON (Alliance News) - Silence Therapeutics PLC on Monday said it has received encouraging results from its Atu027 trials and is planning to progress to a phase two study in the next 18 months.
Alastair Riddell, Silence's chairman, said in a statement due to be given at its annual general meeting that the company has now completed a full interim analysis of the phase 2a trial of Atu027 in pancreatic cancer.
No safety issues were detected in the trials in using Atu027 in combination with gemcitabine, with those exposed to a higher dose of Atu027 showing a longer median duration of progression free survival compared to those on a lower dose regimen.
"We are encouraged by these results and will now work on optimising the dosing schedule in pre-clinical models before planning a larger Phase 2 study in the next 18 months, in which efficacy will be a primary endpoint," said Riddell.
Shares in Silence Therapeutics were up 6.0% to 325.00 pence on Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L